SuperworthSurrozen SRZN
- Market cap
- $299.5M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 26.0×
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- $11.5M
- −9% on a year ago
- Net margin
- n/m
- outside −100% to 100%
- Free cash flow yield
- −11.7%
Surrozen trades at 26.0× sales. Its trailing earnings are negative, so it has no PE. Revenue was $11.5M over the last twelve months, down 9% on a year earlier.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | $0 | $0 | $0 | $10M | $655K | $983K | $983K | $983K−90% | $528K−19% | $5M+409% | $5M+409% | |
| R&D | $6.1M−29% | $6.1M−35% | $5.2M−35% | $5.3M−23% | $5.2M−15% | $5.3M−12% | $6.6M+25% | $6M+13% | $7.8M+50% | $9M+68% | $9.3M+42% | $8.5M+40% |
| SG&A | $3.6M−28% | $3.6M−31% | $3.9M−27% | $3.7M+11% | $3.6M−0% | $3.9M+9% | $4M+2% | $4M+7% | $4.1M+15% | $4.2M+7% | $6.1M+54% | $6.9M+74% |
| −$11.2M−18% | −$9.7M+348% | −$9.1M−37% | −$9M−12% | $1.2M | −$8.6M−12% | −$9.6M+5% | −$9M−0% | −$10.9M | −$12.6M+47% | −$10.5M+10% | −$10.4M+15% | |
| Net income | −$10.4M−22% | −$8.9M+1050% | −$8.8M−38% | −$25.3M+169% | −$1.4M−86% | −$28M+215% | −$27M+205% | $39.7M | −$71.6M+4896% | −$183.2M+553% | −$127.5M+373% | $50.2M+26% |
| −$5.14−10% | −$4.38+1360% | −$4.24−41% | −$7.99+71% | −$0.44−91% | −$8.62+97% | −$7.43+75% | $2.55 | −$8.36+1800% | −$20.13+134% | −$11.65+57% | −$0.41 | |
| 2M−13% | 2M−11% | 2.1M+4% | 3.2M+58% | 3.2M+59% | 3.3M+60% | 3.6M+74% | 8.5M+170% | 8.6M+166% | 9.1M+180% | 10.9M+202% | 23.1M+171% |
EPS, diluted: 6 periods, Q4 FY20 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 5 periods, Q4 FY20 to Q4 FY25: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY23: a loss quarter: its basic count, share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x15).
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Biotechnology nearest Surrozen's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| SRZNSurrozen | $299.5M | n/m | n/a | 26.0× | −9% | n/m | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| MGTXMeiraGTx | $884.6M | 13.0× | 18.0× | 2.2× | n/m | 19.9% | |
| VCELVericel | $2.2B | 92.5× | 158× | 7.1× | +23% | 7.9% | |
| ADMAAdma Biologics | $2.4B | 15.3× | 21.5× | 4.7× | +8% | 33.0% | |
| Peer median | $1.5B | 14.1× | 27.8× | 3.6× | +23% | 21.7% |
More on Surrozen
Each number over time
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .